<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OPC-15006322</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2015-04-28</date_registration>
      <primary_sponsor>Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing</primary_sponsor>
      <public_title>Effective and safety evaluation of human umbilical cord derived mesenchymal stem cells (hU-MSCs)in systemic lupus erythematosus</public_title>
      <acronym />
      <scientific_title>Effective and safety evaluation of human umbilical cord derived mesenchymal stem cells (hU-MSCs)in systemic lupus erythematosus</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2015-06-01</date_enrolment>
      <type_enrolment />
      <target_size>treatment group:35;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=10879</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>I (Phase I study)</phase>
      <hc_freetext>systemic lupus erythematosus</hc_freetext>
      <i_freetext>treatment group:human umbilical cord derived mesenchymal stem cells (hU - MSCs);</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Yi Yang</firstname>
        <middlename />
        <lastname />
        <address>Department of Rheumatology and Immunology,Daping Hospital, Third Military Medical University, Chongqing</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 18502389013</telephone>
        <email>yangyilyx@163.com</email>
        <affiliation>Department of Rheumatology and Immunology,Daping Hospital, Third Military Medical University, Chongqing</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Xiang Xu</firstname>
        <middlename />
        <lastname />
        <address>Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13637843870</telephone>
        <email>xiangxu@ymail.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital;
2. Patients of SLE, to be aged 18 years to 65 years old;
3. All patients fulfilled the 2012 SLICC of SLE classification criteria, SLEDAI &gt;=8;or BILAG score A/B;
4. Lupus nephritis with 24h urine protein&gt;=1g;
5. Refractory disease as determined by failure of the following regimens:
  5.1 Trial of corticosteroids (oral prednisone more than 7.5 mg/day);
  5.2 Trial of cyclophosphamide 0.4~0.6 / m2 every two weeks for six months, or other immunosuppressive drugs, such as MMF 2 g/day, for three months.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Patients with uncorrected disease, such as advanced cancer or other terminal illness, the prospective survival period less than 28 days;
2. Patients in the foreseeable dying state;
3. Have the bone marrow, lungs, liver, pancreas, or small bowel transplantation history;
4. Known or potential of portal hypertension, chronic icteric, chronic liver cirrhosis and ascites; 
5.Have severe heart and lung failure, or irreversible damage or failure of other major organs;
6. Uncontrolled infection; 
7. Patient participating or having participated in a clinical trial with another investigational drug Within 30 days before the start of this clinical trial; 
8. Patient is pregnant or nursing; 
9. History of patient is allergic to biological products; 
10. HIV infected;</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>SLEDAI;BILAG;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Lupus serology;Renal function;Liver function;Routine blood test;Electromyography;Imaging;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>self-financed</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2015-03-06</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>